Phase 3 Study of Experience With a Gonadotropin-releasing Hormone Agonist Prior to Myomectomy - Comparison of 2 Versus 3 Monthly Doses.
Variables noted preoperatively:
- Ultrasound findings
Variables noted intra-operatively:
- Size of largest fibroid
- Estimated blood loss
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment
Intraoperative blood loss
Gonadotropin releasing hormone agonist Goserelin 3.6mg was administered for either 2 or 3 months prior to the operation.
Dr Bharat Bassaw, MBBS FRCOG
Mt. Hope Maternity Hospital
Trinidad and Tobago : Ministry of Health